Figure 3

Figure 3

(A) Western blotting analysis of Akt expression in C2C12 myoblasts after treatment with 5 µg/mL CPP531 for 72 h. GAPDH was used as a loading control. (B) Quantification of Akt expression. (C) Western blotting analysis of phosphorylated Akt (P-Akt) expression in C2C12 myoblasts after treatment with 5 µg/mL CPP531 for 72 h. (D) Quantification of P-Akt expression. (E) RT-PCR analysis of p27^Kip1 and p57^Kip2 mRNA expression in C2C12 myoblasts after treatment with 5 µg/mL CPP531 or 5 μM BIO for 72 h. (F,G) Quantification of p27^Kip1 and p57^Kip2 mRNA expression. (H) Western blotting analysis of p27^Kip1 and p57^Kip2 expression in C2C12 myoblasts after treatment with 5 or 10 µg/mL CPP531, or 5 μM BIO, for 72 h. (I,J) Quantification of p27^Kip and p57^Kip2 protein expression. For (D): *p < 0.05 for significantly increased expression compared to vehicle treated myoblasts. For (F,G) and (I,J): *p < 0.05 for significantly decreased expression compared to vehicle treated myoblasts.